Caris Life Sciences, Inc. (CAI) Fair Value 2026

CAI · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.0 /10

32 fundamental signals · 1 models active

Value Trap Risk

LOW (30/100)

Quick Summary — As of 2026-08-28, Caris Life Sciences, Inc. (CAI) trades at $25.63. QOC: 6.0/10. Value Trap Risk: 30/100 (LOW). 1/13 models active.

Key Facts

Ticker
CAI
Price
$25.63
Quality Score
6.0/10
Value Trap Risk
30/100
Models Active
1/13
Last Updated
Strength: 1 independent models provide multi-angle coverage
Risk: Majority of models suggest overvaluation

What Fair Value Does Each Model Give CAI?

1 Intrinsic Value Models vs. Current Price ($25.63)

Core Models (Unlocked)
Model Fair Value Upside
Relative · Medium Conviction
 $2.25 -91.2%

All Models Active

All 1 models are displayed above.

What Is Caris Life Sciences, Inc. (CAI) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Caris Life Sciences, Inc.'s intrinsic value is estimated at $2.25, suggesting the stock is overvalued at its current price of $25.63. With 1 out of 1 models flagging downside (-91.2% vs price), the market may be pricing in unsustainable growth.

What Do the Models Say About CAI?

1 of 13 models are currently active for CAI. All 1 active models suggest the stock trades above fair value. See which stocks rank higher →

How Does CAI Rank in Biotechnology?

Among 625 Biotechnology stocks, CAI ranks #147 by Quality of Company score. CirclFi's QOC score of 6.0/10 evaluates 32 fundamental signals. A score of 6.0 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

Within the Biotechnology space, Caris Life Sciences, Inc. competes in an environment where cash runway (months) often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.

Is CAI a Value Trap?

CirclFi's Value Trap algorithm assigns CAI a score of 30/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Caris Life Sciences, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Caris Life Sciences, Inc.'s fundamental quality profile registers 6.0/10. This respectable score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every CAI valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across CAI's 1 active models, average confidence is 38%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Caris Life Sciences, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

KURAKura Oncology, Inc.QOC 6.0ISCOInternational Stem Cell CorporationQOC 6.0ALECAlector, Inc.QOC 6.0RANIRani Therapeutics Holdings, Inc.QOC 6.0PRQRProQR Therapeutics N.V.QOC 6.0NUVBNuvation Bio Inc.QOC 6.0RNACCartesian Therapeutics, Inc.QOC 5.1MSLESatellos Bioscience Inc.QOC 4.5EVGNEvogene Ltd.QOC 2.2EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: KURA · ISCO · ALEC · RANI · PRQR · NUVB · RNAC · MSLE · EVGN · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to CAI?

7 companies across all industries closest to CAI’s Quality of Company score of 6.0/10.

DGXXDigi Power X Inc.QOC 6.0OPTXSyntec Optics Holdings, Inc.QOC 6.0NAMIJinxin Technology Holding CompanyQOC 6.0KANPKaanapali Land, LLCQOC 6.0CABRCaring Brands, Inc.QOC 6.0PXEDPhoenix Education Partners, Inc.QOC 6.0NVDANVIDIA CorporationQOC 10.0

Read investment analysis: DGXX · OPTX · NAMI · KANP · CABR · PXED · NVDA

Where Does CAI Sit in CirclFi's Biotechnology Rankings?

CAI is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Caris Life Sciences, Inc.’s Valuation?

What is Caris Life Sciences, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Caris Life Sciences, Inc. (CAI). The Quality of Company score is 6.0/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is CAI overvalued or undervalued right now?

At $25.63, 0 of 1 active models suggest CAI may be undervalued, while 1 indicate potential overvaluation. The assessment depends on which methodology best fits Caris Life Sciences, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 6.0 mean for CAI?

Caris Life Sciences, Inc.'s QOC of 6.0/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on CAI?

CirclFi analyzes CAI with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is CAI a value trap in 2026?

Caris Life Sciences, Inc.'s Value Trap score is 30/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Caris Life Sciences, Inc. (CAI) a Quality of Company score of 6.0/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/CAI/ · Methodology
Primary sources for this CAI valuation
  • Financial statements: Caris Life Sciences, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0002019410) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for CAI as of ; valuations recomputed .